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Despite the overwhelming success of percutaneous cardiac interventions, the interventional practitioner is commonly faced with a number of very simple questions to which the answers should be obvious but are in truth completely unknown. Perhaps the most common such question concerns the appropriate duration of dual antiplatelet therapy (the combination of aspirin and an inhibitor of platelet P2Y12) in patients who have received intracardiac stents.
Most interventional cardiologists receive several such calls per week from patients and professional colleagues, and often have to spend a considerable amount of time negotiating antithrombotic drug treatment strategies in patients who need to undergo non-cardiac surgical procedures.
The truth is that as we enter the third decade of stent use, we know very much less about the need for antithrombotic therapy after stent implantation than physicians (and their patients) would like. Much of our current knowledge is derived from early studies in patients receiving bare metal stents (BMS). When stents were first implanted, the recommended antithrombotic therapy included a variety of marginally effective antiplatelet therapies as well as toxic doses of warfarin and heparin. In 1995, Colombo observed that optimization of stent deployment using ultrasound followed by treatment with aspirin and ticlopidine was associated with lower rates of stent thrombosis, less bleeding, and shorter hospital stays than historical reports. 1 We would probably never have entered the modern stent era without these important observations, which were rapidly confirmed by a series of randomized trials. 2 However, the appropriate duration of thienopyridine therapy after stenting was unknown. While one report indicated that a two week course might be sufficient 3 , the randomized CREDO trial showed that a year of dual antiplatelet therapy reduced the rate of a combined endpoint of death, myocardial infarction or stroke by 27% compared with 30 days of therapy. 4 In fact, this trial, performed more than ten years ago, has been the only trial that until 2010 5 tested the required duration of theinopyridine therapy after stenting.
Drug eluting stents (DES) have been in widespread use for more than a decade and are used in the majority of patients receiving intracoronary stents. In the initial trials, dual antiplatelet therapy was recommended for three months after sirolimus eluting stents and six months after paclitaxel eluting stents were implanted, although many patients in these trials received the drugs for longer periods. The importance of continuing thienopyridine therapy during these periods was strongly reinforced by the observation that premature discontinuation (< 3 months for sirolimus-eluting stents and < 6 months for paclitaxel eluting stents) was an extremely powerful risk factor for stent thrombosis. 6 An early report indicated that neo-intimal coverage of stent struts was nearly complete within thirty days after implantation in experimental animals. 7 However, clinical experience rapidly showed that endothelialization of a first generation DES is incomplete in humans with atherosclerosis, leaving stent struts exposed to the arterial lumen months to years after stent implantation and that thrombi formed at the exposed sites. 8, 9 Such early reports were followed by reports of a continuous hazard of stent thrombosis as high as 0.5% per year for 5 or more years after DES placement. 10, 11 Coupled with observations of unexpected stent thrombosis after clopidogrel was stopped in the BASKET LATE trial 12 , in the Duke Databank 13 and in the Kaiser Permanente database 14 as well as suggestions of a 'rebound' phenomenon in patients whose clopidogrel was terminated following an acute coronary syndrome 15 , such observations led to recommendations for prolonged courses of therapy with clopidogrel after drug DES placement. An AHA/ACCSCAI/ACS/ADA Science Advisory recommends treatment with aspirin and a thienopyridine (presumably extensible to all P2Y12 antagonists) for a minimum of one year after DES implantation 16 , and such recommendations have found their way into various guidelines in the US and Europe. Some observers have recommended an "indefinite" duration of therapy in patients at low risk for bleeding. 17 However, in many other observations, the duration of therapy with thienopyridines beyond either 6 or 12 months had little bearing on the likelihood of late stent thrombosis. 10, 11, 18, 19 Thus, the dilemma faced by clinicians is clear. There is ample evidence that patients who have received DES face a prolonged period during which they are at risk of stent thrombosis and its clinical sequelae. On one hand, the mechanistic explanations would seem to favor continued vulnerability to platelet-mediated thrombosis. However clinical data are at best equivocal concerning the need for prolonged dual antiplatelet therapy. Of course, answering this question would require a randomized trial to overcome the complex confounding that is inevitable in registry and databank studies. The ZEST-LATE and REAL-LATE trials randomized patients who had been event-free on 12 to 18 months of dual antiplatelet therapy after DES to continue aspirin and clopidogrel or to receive aspirin alone. Follow-up lasted for 19 months. Most patients received sirolimus eluting stents with about one fourth receiving paclitaxel eluting stents and < 20% receiving zotarolimus-eluting stents. The trials were designed with an expected event of 5% at two years, but observed rates were < 2%, with a trend favoring the shorter duration of therapy. 5 Valgimgli and the PRODIGY investigators have provided a major next step to answering this issue, by extending the population to include more current generation stents and by shortening the duration of one arm to 6 months of dual antiplatelet therapy. They performed a factorial randomization of more than 2,000 patients to receive either a thin strut BMS, a paclitaxel eluting stent, a zotarolimus eluting stent, or an everolimus eluting stent, and to receive either six or 24 months of dual antiplatelet therapy. All patients received aspirin. Patients receiving BMS who were randomized to 6 months of therapy, could have the therapy stopped at thirty days. Randomization to an antiplatelet strategy was performed thirty days after implantation; the study was designed with 80% power to detect a 40% reduction in a primary endpoint of all cause mortality, myocardial infarction, or stroke. At two years, event rates were considerably higher (10%) than in the LATE trials; no difference was observed in either the primary endpoint, any of its components, or the risk of definite stent thrombosis. There was, however, an excess of bleeding in patients assigned to 24 months of thienopyridine therapy. 20 Thus, two trials comprising nearly 5,000 patients, indicate that courses of clopidogrel exceeding 12 months do not contribute favorably to patient outcomes, and may in fact be detrimental. Both trials included the majority of patients screened and had relatively high proportions of patients with multivessel disease, complex lesions, and high stent lengths. Is it now time to recommend that thienopyridine therapy be terminated after 6 or twelve months of therapy after drug eluting stent implantation? The answer is probably not, for several reasons.
First, and most obvious, a much larger trial, DAPT, is in the process of randomizing > 15,000 patients with DES and > 5,000 patients with BMS to either 12 or 30 months of DAPT, with patients identified at the time of stent implantation, and stratified according to clinical and angiographic "complexity". Results are scheduled to be available in 2014. Unlike either of the two preceding trials, therapy will be blinded and allocation will be masked. 21 Thus, it would make little sense to establish a firm policy while the large and methodologically rigorous trial is still underway.
A number of other issues should cause the PRODIGY and LATE trials to be regarded as preliminary. Neither trial thus far, has been designed to distinguish outcomes between patients with features that suggest high risk (acute coronary syndrome, long stents, bifurcation stents, kidney disease, diabetes) and those whose baseline risk is low. It is entirely conceivable that there will be heterogeneity between such groups. Another important issue to consider is that an increasing number of patients receive treatment with the third generation P2Y12 antagonists prasugrel and ticagrelor. These drugs have greater activity against platelet aggregation than does clopidogrel; the balance between bleeding risk and ischemic event prevention may differ between short and long term therapy when these drugs are used. In the TRITON-TIMI 38 trial, a fifteen month course of prasugrel proved superior to treatment with clopidogrel in patients who underwent coronary interventions for acute coronary syndromes; landmark analysis confirmed that the event curves remained divergent for the fifteen month period. 22 Additionally, an unanticipated mortality benefit was observed in the PLATO trial 23 of ticagrelor compared with clopidogrel. If verified in subsequent trials, these findings may provide rationale for continuing long term P2Y12 antagonism with newer drugs after implanting stents in patients with acute coronary syndromes.
Several other questions require answers as well. A curious and often underappreciated feature of the BASKET LATE trial was that although stent thromboses appeared to cluster after clopidogrel was stopped, they did not occur only during the seven to ten day period when one would have expected the platelet pool to be renewed and circulating platelets fully susceptible to activation. Rather, the median time to stent thrombosis was approximately 90 days. 12 This finding is quite concerning and supports the need for prolonged follow-up in order to allow accurate assessment of the risk (or benefit) of stopping P2Y12 antagonists after stent implantation. The thrombotic system consists of a complex series of prothrombotic and antithrombotic systems that are perpetually in flux but are usually well balanced. Temporal fluctuations in platelet reactivity and in thrombin generation have been documented repeatedly over the last several decades. It may well be that a rare but temporary imbalance between these two systems favoring thrombosis may be all that is required to cause an incompletely endothelialized stent to develop in situ thrombosis after having been stable for a considerable period of time. When one considers that approximately 5% of patients undergo major noncardiac surgery within the first year after stent placement and the risk of myocardial infarction is considerably increased in this setting 24 the case for even longer periods of follow-up, can be made strongly.
A final issue concerns heterogeneity among stent types. There is histopathological evidence that endothelial coverage of stent struts may be greater with current designs compared with early generation DES 9 , and reported rates of stent thrombosis appear to be lower. The LATE trials included patients with predominantly first generation sirolimus eluting stents. In PRODIGY, only one fourth of patients received a paclitaxel eluting stent; twice as many received everolimus or zotarolimus eluting stents. Thus, the power to discern a difference between short and long term dual antiplatelet therapy for paclitaxel eluting stents is limited; for a large number of patients who have previously undergone implantation of a first generation drug eluting stent, the requisite duration of antiplatelet therapy is still unknown and may well be different than that for patients with current generation stents.
How does the overall picture look? There doesn't seem to be much current evidence favoring indefinite dual antiplatelet therapy. However, the view is clouded by the high degree of heterogeneity among patient characteristics, among stent designs and possibly among drug treatments. The conservative (and default) view ought to be that the twelve month duration of therapy was established by the CREDO trial, and that the findings of TRITON-TIMI 38 favor extended therapy in high risk patients. These findings notwithstanding, the logical approach remain to continue dual antiplatelet therapy for a minimum of twelve months in patients who have received DES with longer durations currently reserved for patients who have had complex presentations or difficult stent procedures, while reserving earlier termination for patients with poor drug tolerance, all the while awaiting the results of the more definitive DAPT study.
